Active substance
Results for the substance binimetinib
1 result
About this active substance
Binimetinib is a medication used in the treatment of certain types of cancer, particularly advanced or metastatic melanoma with BRAF gene mutations. It is a MEK kinase inhibitor that blocks a specific cellular signaling pathway involved in the growth and division of cancer cells.
The medication is taken orally, usually twice daily, as directed by a doctor. It is often used in combination with other drugs, such as encorafenib, to enhance treatment effectiveness.
Common side effects include nausea, diarrhea, fatigue, skin rashes, and abdominal pain. In some cases, more serious adverse effects, such as heart or eye problems, may occur, requiring regular monitoring of patients.
Binimetinib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications and supplements they are taking to avoid drug interactions.
The medication is taken orally, usually twice daily, as directed by a doctor. It is often used in combination with other drugs, such as encorafenib, to enhance treatment effectiveness.
Common side effects include nausea, diarrhea, fatigue, skin rashes, and abdominal pain. In some cases, more serious adverse effects, such as heart or eye problems, may occur, requiring regular monitoring of patients.
Binimetinib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications and supplements they are taking to avoid drug interactions.